Giredestrant in HR+/HER2- advanced breast cancer
In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors
Day: May 27, 2024
In the phase II aceIERA trial, giredestrant was well tolerated and showed a trend toward favorabile benefit among ESR-1 mutated tumors